BioinvestGPT

BioinvestGPT ApS · Research use only

NCT06449209 (Pumitamig in untreated extended-stage small-cell lung cancer): BVCT ex-ante prediction vs. reported outcome

On 9 Aug 2025, BioinvestGPT's BVCT predicted technical partial success and commercial partial success for this trial. The 8 Sep 2025 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically significant (numerically superior in ORR/PFS) and commercially TBD.

Clinical Trial

NCTID
NCT06449209
Drug Name
Pumitamig (BNT327)
Drug MoA
anti-PDL1 and anti-VEGF
Drug Modality
bispecific antibody (bsAb)
Drug Class
First-In-Class
Therapeutic Area
Neoplasms
Indication
untreated extended-stage small-cell lung cancer (ES-SCLC)
Human Patients
110
Sponsor
BioNTech
Phase
Phase 2

Prediction of , index 1729

Prospective Prediction
Prediction Index
1729
Prediction Date
Commercial Prediction
partial SUCCESS (commercially maybe sufficient yet moderate additive clinical benefit in OS numerically superior to ICI+chemotherapy as 1L treatment and numerically superior to chemotherapy as 2L/3L treatment)
Technical Prediction
partial SUCCESS (statistically significant yet moderate additive clinical benefit in ORR/PFS numerically superior to ICI+chemotherapy as 1L treatment and numerically superior to chemotherapy as 2L/3L treatment)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
30 days in advance
Readout Data Interpretation
Pumitamig + chemotherapy achieved 76.3% cORR and 6.8 months mPFS; numerically superior to the SoC atezolizumab + chemotherapy that achieved 60% cORR and 5.2 months mPFS (see add'l link below); wait for OS data
Press Release
Additional Readout Data
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant (numerically superior in ORR/PFS) and commercially TBD
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase II, Multi-site, Open-label, Parallel Group Trial of BNT327 in Combination With Chemotherapy for Participants With Untreated Extensive-stage Small-cell Lung Cancer and Participants With Previously Treated Small-cell Lung Cancer
Phase
Phase 2
Status
Active not recruiting
Enrollment
110
Lead sponsor
BioNTech SE
Conditions
Extensive-stage Small-cell Lung Cancer; Small-cell Lung Cancer
Interventions
DRUG: BNT327 Dose Level 1 (DL1); DRUG: BNT327 Dose Level 2 (DL2); DRUG: Etoposide; DRUG: Carboplatin; DRUG: Paclitaxel; DRUG: Topotecan
Design
Randomized · Parallel · None
Primary purpose
Treatment
Start
2024-08-05
Primary completion
2027-06
Completion
2028-02
Primary outcomes
  • Occurrence of treatment emergent adverse events (TEAEs), adverse events of special interest (AESIs), treatment-related TEAEs, treatment-related serious adverse events (SAEs) and treatment-related treatment emergent SAEs (up to 100 days after the last dose of treatment)
  • Occurrence of dose interruption, reduction, and discontinuation of study treatment due to TEAEs (up to 100 days after the last dose of treatment)
  • Objective Response Rate (until end-of-treatment visit, i.e., up to 24 months after the first dose of treatment)
  • Best percentage change from baseline in the tumor size (Until end-of-treatment visit, i.e., up to 24 months after the first dose of treatment)
  • Proportion of participants who have achieved early tumor shrinkage (up to 2 months after first dose of treatment)

NCT06449209 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials